Payment overview · 2025
General Payments
$170.33
10 reported records · 4 companies
Healthcare provider profile · identity verified
Suzanne Stark, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RICHLAND, GA · NPI 1053406199
Verified facts
What the public records show
CMS Open Payments records show Suzanne Stark, FNP received $170.33 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.36 | 50.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.77 | 28.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.44 | 12.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.76 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.33 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.36 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.36 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.77 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 569 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 429 | 108 |
| Potassium Chloride | Potassium Chloride | 251 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 52 |
| Losartan Potassium | Losartan Potassium | 234 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 43 |
| Lisinopril | Lisinopril | 219 | 52 |
| Omeprazole | Omeprazole | 218 | 57 |
| Gabapentin | Gabapentin | 215 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 85 |
| Carvedilol | Carvedilol | 179 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 175 | 36 |
| Tramadol Hcl | Tramadol Hcl | 169 | 30 |
| Ozempic | Semaglutide | 163 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 160 | 33 |
| Furosemide | Furosemide | 156 | 47 |
| Metformin Hcl | Metformin Hcl | 151 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 35 |
| Allopurinol | Allopurinol | 124 | 26 |
| Nifedipine Er | Nifedipine | 122 | 25 |
| Sertraline Hcl | Sertraline Hcl | 122 | 23 |
| Prednisone | Prednisone | 108 | 76 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 26 |
| Metformin Hcl Er | Metformin Hcl | 104 | 23 |
| Jardiance | Empagliflozin | 99 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 34 |
| Montelukast Sodium | Montelukast Sodium | 90 | 24 |
| Trazodone Hcl | Trazodone Hcl | 90 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 18 |
| Linzess | Linaclotide | 75 | suppressed |
| Valsartan | Valsartan | 73 | 18 |
| Eliquis | Apixaban | 71 | 11 |
| Glimepiride | Glimepiride | 70 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 12 |
| Famotidine | Famotidine | 65 | 15 |
| Amoxicillin | Amoxicillin | 62 | 48 |
| Meloxicam | Meloxicam | 61 | 17 |
| Pregabalin | Pregabalin | 61 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 13 |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | 13 |
| Simvastatin | Simvastatin | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Risperidone | Risperidone | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Colchicine | Colchicine | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Naproxen | Naproxen | 30 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | 11 |
| Atenolol | Atenolol | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Ibu | Ibuprofen | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Posaconazole | Posaconazole | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.33 · 10 records | Novo Nordisk Inc | AIRSUPRA, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error